The online marketplace for outsourced research has expanded its compliance solution to include animal welfare – and is working with customers to increase transparency and educate researchers.
phaseUP is a new life sciences leadership firm that is looking to help pharma, biotech, and CROs build cohesive and collaborative teams – as the success or failure of a clinical development program depends on the people, says company founder.
Clinical trials are less safe today as researchers are inundated with increasing amounts of data and new processes developed in part by CROs, which have created “tier upon tier of bureaucracy,” argues industry expert, who warns that things are getting...
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
Strategikon Pharma releases new modules for its Clinical Maestro software suite – another step in the company’s journey to harmonize sponsor and CRO operations, with further updates slated for later this year, says CCO.
Scientist.com has more than 70 employees across the globe, with offices in San Diego, Boston, the UK – and soon, Japan, with plans to open several satellite offices across the country.
Sygnature Discovery is adding a new facility at Alderley Park in Cheshire, UK in response to an increasing demand for outsourced preclinical research services.
Outsourcing-Pharma recently conducted a second ‘state of the industry’ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.
UDG Healthcare has acquired two healthcare-focused firms, expanding its global footprint and service offerings – including those in health economics and outcomes research – in a deal worth up to $82.4m.
There is an increased need for transparency to improve the conduct of pediatric clinical trials and enhance the site investigator experience, says Syneos executive.
Iqvia has launched a new suite of virtual study options to challenge the traditional clinical research mindset with a patient-centric approach, says company executive.
Charles River has reported strong Q3 sales despite weakness in Japan and plans to grab space in emerging early discovery, bio-testing and Chinese markets.
As biopharmaceutical companies look to cut costs and understand their core competencies further, the use of outsourcing and off-shoring have become even more mainstream than in years past, according to the 12th annual biomanufacturing report from BioPlan...
As PRA Health Services goes public this week, nearly all of the top CROs are now public and the top tier of these companies could control about half of the outsourcing industry, Parexel CFO Ingo Bank said Tuesday.
The opening of a global IT centre in India will bring services back in-house, but AstraZeneca says it is not changing its outsourcing strategy for R&D and manufacturing.
As small and medium sized biopharma companies continue to raise cash through IPOs and elsewhere, CROs will see an uptick in outsourced work, Parexel founder, chairman and CEO Joseph von Rickenbach predicted in the company’s earnings call last week.
Phase II and III research is expected to see the biggest upturn in terms of outsourcing from large and medium-sized pharma, according to a survey from the Life Sciences Strategy Group.
As the Pfizer-AstraZeneca mega-merger seems to be pushing towards a deal, early phase CROs may be the first to suffer for a short period of time directly after the merger is complete, some say, while others don't seem to think there will be much...
Parexel says a service which manages regulatory activities for already approved drugs fills a gap in the market for pharmaceutical companies feeling the pressure to be efficient.
Changes at PTI, a new CEO at CROS and SCM Pharma’s US expansion head up the executive changes in this week’s Outsourcing-pharma.com’s People on the Move column.
Contract manufacturing organisations (CMOs) have been busy in the past week, with OsoBio expanding its plant and AMRI adopting a new relationship strategy.
Outsourcing is a gamble for the industry that needs a closer collaborative approach if pharma firms want a successful performance, according to new research.
Quintiles says its alliance with Intarcia Therapeutics – developer of an injection-free diabetes drug – uses a financing model that could replace “old-fashioned” outsourcing business relationships.
In September Outsourcing-pharma held Patient Recruitment Outsourcing (PRO) in Boston, bringing together the movers and shakers in the recruitment sector. Robert Loll, vice president of business development, shares his thoughts on the event with a particular...
In the first of a series of special in-pharmatechnologist podcasts Kate Wilber, Image Solutions’ (ISI) director of regulatory Services, Europe discusses the emerging trends in BPO and talks about how it can benefit drugmakers.
More than 50 per cent of large pharma keep all pharmacovigilance in-house but among smaller firms, and even some big businesses, outsourcing is considerable, according to a new report.
Johnson Controls has secured a five year global contract to provide GlaxoSmithKline (GSK) with workplace services, such as energy management and technical and engineering support.
Satyam, the Indian IT outsourcing company whose former chairman admitted to a $1bn (€700m) fraud in January, has posted a $10.9m unaudited profit for February, sending shares soaring.
Pfizer has enlisted outsourcing services firm NovaMed
Pharmaceuticals to conduct the distribution, sales and marketing of
some of its products in the country.
Affiliated Computer Services (ACS) is on the receiving end of
Allergan's decision to outsource its IT functions, inking a $130m
contract with the specialty pharma firm.
Merck & Co. has just inked "multi-million dollar" deal
with Cognizant, at a time when the US-based IT services firm is
pursuing a greater presence in the life sciences sector.
Outsourcing Services Group (OSG) has announced it has sold its
contract manufacturing subsidiary OSG Norwich Pharmaceuticals to a
US private equity firm for an undisclosed amount.
Procter & Gamble (P&G) has announced its intention to
outsource the active pharmaceutical ingredient (API) R&D and
manufacturing work undertaken at one of its US factories, with
resultant closure of the site and job losses.
Outsourced pharmaceutical R&D spending is set to increase
at twice the expected rate of general R&D expenditure
for the next five years, according to new research published this
week.
